HLA-C*08:02 Lentivirus

Catalog #

78930

$835 *

Size: 500 µl x 2

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

HLA-C*08:02 Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. These viruses result in expression of human HLA-C*08:02 driven by an EF1a promoter and a puromycin selection marker (Figure 1).

Figure 1. Schematic of the lenti-vector used to generate HLA-C*08:02 Lentivirus.

●

Product Data Gallery

Expression of HLA-C*08:02 in K562 cells transduced with HLA-C*08:02 Lentivirus

Product Info

Storage and Usage

Citations

Supplied As

Two vials (500 µl x 2) of lentivirus at a titer ≥10⁷ TU/ml. The titer will vary with each lot; the exact value is provided with each shipment

Formulation

The lentivirus particles were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations by special request, for an additional fee.  

Background

Human Leukocyte Antigen-C (HLA-C) are MHC (major histocompatibility complex) I heavy chain receptor, composed of HLA-C and β2-microglobulin (B2M). HLA-C is present in all cells and exists as several haplotypes due to the diversity of HLA-C genes. C*08:02 represents one such haplotype. HLA class I present neoantigen derived peptides to the cell surface, allowing them to be recognized by T cells, via TCR (T cell receptors). Cancer immunotherapy has been taking advantage of that mechanism, by engineering T cells to express TCRs able to recognize specific cancer immunogens. In 2016 the use of HLA-C*08:02-restricted TIL (tumor infiltrating lymphocytes) targeting specifically KRAS (Kirsten rat sarcoma virus) G12D mutation in lung cancer resulted in positive results. Last year a similar approach was pursued in a patient with metastatic pancreatic cancer and resulted in regression of the disease. The study of HLA-C*08:02-restricted TIL expressing TCR against other neoantigens may prove beneficial in cancer therapy.

References

Leidner R., et al., 2022 N Engl J Med 386:2112-2119
Tran E., et al., 2016 N Eng J Med 375:2255-2262.

Storage/Stability

Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.

Applications

Expression of human HLA-C*08:02 in cells of interest.
Generate cell pools or stable cell lines expressing HLA-C*08:02 following puromycin selection.

Shipping Temperature

-80°C

Notes

To generate an HLA-C*08:02 expressing stable cell line, remove the growth medium 48 hours after transduction and replace it with fresh growth medium containing the appropriate amount of puromycin (as pre-determined from a killing curve, https://bpsbioscience.com/cell-line-faq), for antibiotic selection of transduced cells, following by clonal selection

Biosafety
The lentiviruses are produced with a SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and after integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS Bioscience recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions

Troubleshooting Guide
Visit bpsbioscience.com/lentivirus-faq for detailed troubleshooting instructions. For further questions, please email [email protected].

Warnings

Avoid freeze/thaw cycles

Scientific Category

Immune Cell Signaling

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

HLA-C*08:02 Lentivirus

PRODUCTS

SERVICES

RESOURCES

COMPANY